Digital Commons Network^™

Transitions To Normal Saline Only For Cvads, Megan Lehn, Ann Backes

Nursing Posters

Purpose Statement:

The purpose of this project is to implement a practice change throughout the system to remove heparin flushes for Central Venous Access Devices (CVADS) pending a successful pilot on Medical Oncology.

Synthesis of Evidence:

• Shama et al (2019) conducted a systematic review and meta-analysis including 886 participants that revealed no clear differences in CVC patency between heparin and NS.
• Klein et al (2018) conducted a pilot study on a 30-patient bone marrow transplant unit, each patient had a new CVC and were divided into two groups. Among 698 catheter-associated events overall incidence of central line issues were similar …

Retrospective Evaluation Of Weight Based Heparin Protocol In Morbidly Obese Patients For The Treatment Of Venus Thromboembolism, Parth J. Patel, Brady Mcmahon, Christina Yang

Gulf Coast Division GME Research Day 2022

No abstract provided.

Decreasing Unnecessary Pharmacy Cost In The Cath Lab, Scott M. Scepaniak, Kristi Patterson

Nursing Posters

AngioMax is a single dose heparin alternative introduced in 2002 that is used in cardiac patients undergoing percutaneous intervention (PCI). Bivalirudin costs $377 per dose; heparin is less than $15 per dose. Noting practice variations, the Cath Lab set out to eliminate unnecessary pharmacy cost for PCI patients by:

• Using current literature to inform clinical care
• Standardizing practice
• Using data to track and guide implementation

Pharmacy & Therapeutics Update: Drug Information For Health Care Professionals, October 2009, Medical University Of South Carolina, Heather Kokko, Kelli Garrison, Jason Cooper, Chris Wisniewski, Jimmy New

Pharmacy & Therapeutics Update: Drug Information for Health Care Professionals

No abstract provided.